MIAMI--(BUSINESS WIRE)--ChemoCentryx, Inc. is presenting clinical and preclinical data from studies of the company’s drug candidate Traficet-EN® (CCX282-B) a first-in-class, orally active, anti-inflammatory agent that targets the chemokine receptor known as CCR9, at the 2006 Crohn’s and Colitis Foundation of America’s (CCFA) National Research and Clinical Conference/Fifth Annual Advances in the Inflammatory Bowel Diseases meeting being held December 1-3, 2006 in Miami, FL. New data from a Phase 2 clinical trial of patients with moderate-to-severe Crohn’s disease are being presented analyzing the effect of Traficet-EN on lowering pro-inflammatory cytokine and chemokine concentrations in the intestine. These findings complement earlier data showing improved clinical endpoints in Crohn’s disease from the Phase 2 clinical trial.
